Drug Trial Radar · NCT02666157
Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
Last checked: Nov 20, 2026Latest source record: Feb 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,672
Planned (sponsor's estimate)
Start
Jan 2016
Primary completion
Dec 2018
Study completion Dec 2018
Sponsor
- Lead sponsor
- National Cheng-Kung University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tainan Municipal Hospital; E-DA Hospital; National Cheng-Kung University Hospital Dou-Liou Branch; Ministry of Health and Welfare, Taiwan
- First posted
- Jan 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. The recent development of novel oral anticoagulants (NOACs), including direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), could potentially overcome many drawbacks of warfarin, and might provide a safer, and even more effective and convenient alternative approach to warfarin in non-valvular atrial fibrillation (NVAF), especially in Asians. 2. According to the results of a meta-analysis comparing Asians and non-Asians, NOACs are preferentially indicated in Asians in terms of both efficacy and safety. 3. There is no randomized controlled trial with sufficient power to directly compare the efficacy and safety among NOACs in NVAF, not to speak of Asians and Chinese. 4. Indirect comparisons are only based on observation with a lot of limitations such as heterogeneous background characteristics, difference in study design, and diversity in time within therapeutic range in control group. The findings from indirect comparisons are not conclusive but only hypothesis-generating. 5. This investigator-initiated prospective randomized open blinded end-point clinical trial will directly compare the efficacy and safety among 3 NOACs in patients with NVAF in Taiwan. We hypothesize that rivaroxaban or apixaban is non-inferior to dabigatran in terms of the efficacy.
Conditions
- Atrial Fibrillation
Interventions
Dabigatran etexilateDrug
this drug is administered twice per day for the entire study period
RivaroxabanDrug
this drug is administered once per day for the entire study period
ApixabanDrug
this drug is administered twice per day for the entire study period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the occurrence of the major embolic eventsTime frame: up to 36 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
National Cheng Kung University Hospital Dou-Liou Branch
Dou-Liou City, Taiwan · Not yet recruiting
E-DA Hospital
Kaohsiung City, Taiwan · Not yet recruiting
Tainan Municipal Hospital
Tainan, Taiwan · Recruiting
National Cheng Kung University Hospital
Tainan, Tainan City, Taiwan · Recruiting
Tainan Hospital Ministry of Health and Welfare
Tainan, Tainan City, Taiwan · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.